Progression of Hematopoietic Diseases in Shanghai, China

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by University of Colorado, Denver.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Fudan University
University of Cincinnati
ExxonMobil Biomedical Sciences, Inc.
British Petroleum-Amoco
Chevron
ConocoPhillips
Exxon Mobil
Marathon Ashland
Shell Chemicals
Information provided by:
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00365014
First received: August 14, 2006
Last updated: May 23, 2007
Last verified: May 2007

August 14, 2006
May 23, 2007
August 2003
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00365014 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Progression of Hematopoietic Diseases in Shanghai, China
Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility.

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility. The format for these studies is a set of clinical series superimposed on a case-control design that enables integration of detailed clinical and molecular characterizations of disease pathogenesis together with an evaluation of potential confounding and interacting factors within a structured statistical analysis of benzene exposure.

Observational
Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Hematologic Diseases
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10757
April 2008
Not Provided

Inclusion Criteria:

Men and women 18 years or older Diagnosis of hematologic abnormality

Exclusion Criteria:

Children Non hematologic diseases

-

Both
18 Years and older
No
Contact: Sherilyn A. Gross, PhD 303-315-1659 Sherilyn.gross@uchsc.edu
China
 
NCT00365014
02-036
Not Provided
Not Provided
University of Colorado, Denver
  • Fudan University
  • University of Cincinnati
  • ExxonMobil Biomedical Sciences, Inc.
  • British Petroleum-Amoco
  • Chevron
  • ConocoPhillips
  • Exxon Mobil
  • Marathon Ashland
  • Shell Chemicals
Principal Investigator: Richard D Irons, PhD University of Colorado at Denver and Health Sciences Ctr.
University of Colorado, Denver
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP